Log in

Please remember registration is not considered complete until payment has been received by the BBANYS Central Office. Upon receipt of payment, you will receive a confirmation email. If you have any questions, please contact bbanys@bbanys.org.

March 10, 2021 Webinar - Genomics in Sickle Cell Disease

  • Wednesday, March 10, 2021
  • 3:00 PM - 4:00 PM (EST)
  • Online

Registration

  • Includes access to all four sessions for current webinar series - do not need to register individually for other sessions in the series
  • Includes access to all four sessions for current webinar series - do not need to register individually for other sessions in the series
  • Includes access to all four sessions for current webinar series - do not need to register individually for other sessions in the series

Registration is closed

Wednesday, March 10, 2021 / 3:00 PM - 4:00 PM EST

Topic: Genotyping for Improved Outcomes in Chronic Transfusion Sickle Cell Patient

Speaker:

Ghazala Nathu, MD, MS, PhD, FACB

Abstract: 
Blood transfusions are often an important component of medical care for many patients. Certain patients afflicted with blood disorders or certain chronic illnesses may require routine blood transfusions to maintain health. However, there are risks and side effects to blood transfusions. Every blood transfusion requires pre-transfusion testing to ascertain antigen and antibody compatibility between donor and recipient blood cells in order to prevent hemolytic transfusion reactions. The conventional method of routine serological blood phenotyping has allowed for a lower risk of alloimmunization in chronically transfused patients however it can be expensive and sometimes ineffective. DNA-based molecular testing using microarrays is a newer technique that can be used to more effectively match and guide blood transfusion decisions, especially in chronically transfused patients. The molecular methods of blood group genotyping can be utilized in prenatal medicine to differentiate between weak D and partial D antigens. This allows for better clinical usage of Rh prophylaxis in patients and reduces risk of fetal hemorrhage and other complications. As such, this work explores the role of molecular blood typing techniques in reducing the risk of alloimmunization, the potential for identifying uncommon antigens in transplant cases, and decreasing unnecessary usage of Rh prophylaxis in prenatal medicine.

Objectives:

  1. Explain the role of Molecular/Clinical testing order and interpreting test results in Immunohematology.
  2. Describe the methodology of DNA-based bead array technology.
  3. Recognize the current limitations of molecular testing and interpreting tests results.
  4. Identify what causes a reduction in alloimmunization.
Pricing:
  • Member: $20 per session & $55 entire series
  • Non-Member: $45 per session & $130 entire series
  • Institution: $75 per session & $200 entire series

To receive member pricing, be sure to sign in.




BLOOD BANKS ASSOCIATION OF NEW YORK STATE
COPYRIGHT © 2021

CONTACT US
Phone: 866-397-8883
Fax: 651-317-8048
Email: bbanys@bbanys.org

ADDRESS
BBANYS
2345 Rice Street, Suite 220
St. Paul, MN 55113

Powered by Wild Apricot Membership Software